Literature DB >> 1748041

CP-66,948: an antisecretory histamine H2-receptor antagonist with mucosal protective properties.

J P Hakkinen1, W F Holt, C J Goddard, P J Oates, W R Murphy, J J Maciejko, L A Reiter.   

Abstract

CP-66,948 is a histamine H2-receptor antagonist with gastric antisecretory activity and mucosal protective properties. The affinity of CP-66,948 for the guinea pig atria histamine H2-receptor is 15 times greater than that of cimetidine and seven times greater than that of ranitidine. In vivo, the ED50 value for inhibition of gastric acid secretion in pylorus-ligated rats is 2 mg/kg intraduodenally, and in histamine or pentagastrin-stimulated Heidenhain pouch dogs the antisecretory ED50 values are 0.3 mg/kg per os and 1.0 mg/kg per os, respectively. CP-66,948 also inhibits ethanol-induced gastric hemorrhagic lesions in rats following either oral or systemic administration (ED50 values of 12 mg/kg per os and 6 mg/kg subcutaneously). In addition, the mucosal protective activity is independent of prostaglandin synthesis. CP-66,948 inhibits gastric acid secretion in man, and its mucosal protective activity may provide additional benefits in peptic ulcer therapy.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1748041     DOI: 10.1007/bf01296616

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  16 in total

1.  Techniques in Heidenhain pouch experiments.

Authors:  R V DeVITO; H N HARKINS
Journal:  J Appl Physiol       Date:  1959-01       Impact factor: 3.531

2.  Formation of prostacyclin and its product 6-oxo-PGF1alpha by the gastric mucosa of several species [proceedings].

Authors:  S Moncada; J A Salmon; J R Vane; B J Whittle
Journal:  J Physiol       Date:  1978-02       Impact factor: 5.182

3.  Definition and antagonism of histamine H 2 -receptors.

Authors:  J W Black; W A Duncan; C J Durant; C R Ganellin; E M Parsons
Journal:  Nature       Date:  1972-04-21       Impact factor: 49.962

4.  Cytoprotection by prostaglandins in rats. Prevention of gastric necrosis produced by alcohol, HCl, NaOH, hypertonic NaCl, and thermal injury.

Authors:  A Robert; J E Nezamis; C Lancaster; A J Hanchar
Journal:  Gastroenterology       Date:  1979-09       Impact factor: 22.682

5.  A comparison of some of the pharmacological properties of etintidine, a new histamine H2-receptor antagonist, with those of cimetidine, ranitidine and tiotidine.

Authors:  R L Cavanagh; J J Usakewicz; J P Buyniski
Journal:  J Pharmacol Exp Ther       Date:  1983-01       Impact factor: 4.030

6.  Gastric cytoprotection by prostaglandins, ranitidine, and probanthine in rats. Role of endogenous prostaglandins.

Authors:  S J Konturek; T Radecki; T Brzozowski; I Piastucki; A Dembińska-Kieć; A Zmuda
Journal:  Scand J Gastroenterol       Date:  1981       Impact factor: 2.423

7.  Some in vitro and in vivo actions of the new histamine H2-receptor antagonist, ranitidine.

Authors:  M J Daly; J M Humphray; R Stables
Journal:  Br J Pharmacol       Date:  1981-01       Impact factor: 8.739

8.  Some quantitative uses of drug antagonists.

Authors:  O ARUNLAKSHANA; H O SCHILD
Journal:  Br J Pharmacol Chemother       Date:  1959-03

9.  Comparison of the gastric cytoprotective properties of atropine, ranitidine and PGE2 in rats.

Authors:  P Del Soldato; D Foschi; L Varin; S Daniotti
Journal:  Eur J Pharmacol       Date:  1984-10-30       Impact factor: 4.432

10.  Mild irritants prevent gastric necrosis through "adaptive cytoprotection" mediated by prostaglandins.

Authors:  A Robert; J E Nezamis; C Lancaster; J P Davis; S O Field; A J Hanchar
Journal:  Am J Physiol       Date:  1983-07
View more
  1 in total

1.  JB-9322, a new selective histamine H2-receptor antagonist with potent gastric mucosal protective properties.

Authors:  B Palacios; M J Montero; M A Sevilla; L S Román
Journal:  Br J Pharmacol       Date:  1995-05       Impact factor: 8.739

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.